Ratings by Barclays (Peter Lawson)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
5/28/2021 Adaptimmune Therapeutics plc ADAP New Coverage Underweight
(N/A)
4.98
(5.76)
15.66% Details
5/28/2021 CytomX Therapeutics CTMX Downgrade Underweight
(Equalweight)
8.22
(5.26)
-36.01% Details
5/19/2021 Iovanace Biotherapeutics IOVA Maintain Overweight
(N/A)
 
 
  Details
5/5/2021 Deciphera DCPH Maintain Overweight
(N/A)
 
 
  Details
4/30/2021 Agios Pharma AGIO Maintain Overweight
(N/A)
 
 
  Details
3/12/2021 MacroGenics MGNX Upgrade Overweight
(Underweight)
27.63
(19.74)
-28.56% Details
2/26/2021 Spring Works Therapeutics SWTX Maintain Overweight
(N/A)
 
 
  Details
2/25/2021 Arcus Biosciences RCUS Maintain Overweight
(N/A)
 
 
  Details
2/24/2021 Xencor, Inc. XNCR Maintain Underweight
(N/A)
 
 
  Details
2/18/2021 Blueprint Medicines BPMC Maintain Equalweight
(N/A)
 
 
  Details
2/12/2021 Karyopharm Therapeutics KPTI Maintain Overweight
(N/A)
 
 
  Details
2/10/2021 Deciphera DCPH Maintain Overweight
(N/A)
 
 
  Details
1/27/2021 Agios Pharma AGIO Maintain Overweight
(N/A)
 
 
  Details
1/15/2021 Fate Therapeutics FATE Maintain Overweight
(N/A)
 
 
  Details
12/17/2020 Y-mAbs Therapeutics YMAB Maintain Overweight
(N/A)
 
 
  Details
12/17/2020 Spring Works Therapeutics SWTX Maintain
(N/A)
 
 
  Details
12/17/2020 MacroGenics MGNX Maintain Underweight
(N/A)
 
 
  Details
12/17/2020 Iovanace Biotherapeutics IOVA Maintain Overweight
(N/A)
 
 
  Details
12/17/2020 Fate Therapeutics FATE Maintain Overweight
(N/A)
 
 
  Details
12/7/2020 Syndax Pharmaceuticals SNDX Maintain Overweight
(N/A)
 
 
  Details
12/7/2020 Kura Oncology KURA Maintain Overweight
(N/A)
 
 
  Details
12/7/2020 Fate Therapeutics FATE Maintain Overweight
(N/A)
 
 
  Details
12/2/2020 Fate Therapeutics FATE Maintain Overweight
(N/A)
 
 
  Details
11/19/2020 Syndax Pharmaceuticals SNDX Maintain Overweight
(N/A)
 
 
  Details
11/12/2020 Xencor, Inc. XNCR Maintain Underweight
(N/A)
 
 
  Details
11/9/2020 Y-mAbs Therapeutics YMAB Maintain Overweight
(N/A)
 
 
  Details
11/9/2020 Epizyme EPZM Maintain Overweight
(N/A)
 
 
  Details
11/9/2020 CytomX Therapeutics CTMX Maintain Equalweight
(N/A)
 
 
  Details
11/6/2020 Iovanace Biotherapeutics IOVA Maintain Overweight
(N/A)
 
 
  Details
10/22/2020 Agios Pharma AGIO Upgrade Overweight
(Equalweight)
35.39
(47.52)
34.28% Details
10/7/2020 Y-mAbs Therapeutics YMAB Maintain Overweight
(N/A)
 
 
  Details
10/6/2020 Iovanace Biotherapeutics IOVA Maintain Overweight
(N/A)
 
 
  Details
9/30/2020 Kura Oncology KURA Maintain Overweight
(N/A)
 
 
  Details
9/23/2020 Blueprint Medicines BPMC Maintain Equalweight
(N/A)
 
 
  Details
8/31/2020 Kura Oncology KURA Maintain Overweight
(N/A)
 
 
  Details
8/13/2020 Spring Works Therapeutics SWTX Maintain Overweight
(N/A)
 
 
  Details
8/6/2020 Immunomedics IMMU Maintain Overweight
(N/A)
 
 
  Details
6/23/2020 Karyopharm Therapeutics KPTI Maintain Overweight
(N/A)
 
 
  Details
6/8/2020 Y-mAbs Therapeutics YMAB Maintain
(N/A)
 
 
  Details
6/4/2020 Replimune Group REPL Maintain Overweight
(N/A)
 
 
  Details
5/22/2020 Syndax Pharmaceuticals SNDX Maintain Overweight
(N/A)
 
 
  Details
5/18/2020 Deciphera DCPH Maintain Overweight
(N/A)
 
 
  Details
5/8/2020 CytomX Therapeutics CTMX Maintain Equalweight
(N/A)
 
 
  Details
5/5/2020 Immunomedics IMMU New Coverage Overweight
(N/A)
30.38
(87.86)
189.2% Details
5/5/2020 Y-mAbs Therapeutics YMAB New Coverage Overweight
(N/A)
32.39
(28.70)
-11.39% Details
5/5/2020 Blueprint Medicines BPMC New Coverage Equalweight
(N/A)
57.15
(106.61)
86.54% Details
5/5/2020 Replimune Group REPL New Coverage Overweight
(N/A)
16.21
(32.26)
99.01% Details
5/5/2020 Kura Oncology KURA New Coverage Overweight
(N/A)
13.88
(20.25)
45.89% Details
5/5/2020 Spring Works Therapeutics SWTX New Coverage Overweight
(N/A)
30.21
(68.70)
127.41% Details
5/1/2020 Agios Pharma AGIO Maintain Equalweight
(N/A)
 
 
  Details
3/4/2020 CytomX Therapeutics CTMX New Coverage Equalweight
(N/A)
7.30
(5.26)
-27.95% Details
3/4/2020 Karyopharm Therapeutics KPTI New Coverage Overweight
(N/A)
27.72
(6.26)
-77.42% Details
3/4/2020 Fate Therapeutics FATE New Coverage Overweight
(N/A)
31.01
(64.85)
109.13% Details
3/4/2020 Arcus Biosciences RCUS New Coverage Overweight
(N/A)
17.59
(35.97)
104.49% Details
3/4/2020 Deciphera DCPH New Coverage Overweight
(N/A)
57.02
(32.79)
-42.49% Details
3/4/2020 Exelixis EXEL New Coverage Overweight
(N/A)
19.29
(20.35)
5.5% Details
3/4/2020 Syndax Pharmaceuticals SNDX New Coverage Overweight
(N/A)
9.80
(18.80)
91.84% Details
3/4/2020 MacroGenics MGNX New Coverage Underweight
(N/A)
8.89
(19.74)
122.05% Details
3/4/2020 Agios Pharma AGIO New Coverage Equalweight
(N/A)
49.34
(47.52)
-3.69% Details
3/4/2020 Iovanace Biotherapeutics IOVA New Coverage Overweight
(N/A)
35.99
(24.96)
-30.65% Details
3/4/2020 Nektar Therapeutics NKTR New Coverage Overweight
(N/A)
20.10
(18.51)
-7.91% Details
3/4/2020 Xencor, Inc. XNCR New Coverage Underweight
(N/A)
32.28
(33.88)
4.96% Details
3/4/2020 Epizyme EPZM New Coverage Overweight
(N/A)
22.99
(5.33)
-76.82% Details